Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Lipid-lowering therapy in low-risk patients.

Pearson TA.

JAMA. 1998 May 27;279(20):1659-61. No abstract available.

PMID:
9613918
2.
3.

Comparative efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and placebo in type 2 diabetic patients with hypercholesterolaemia.

Gentile S, Turco S, Guarino G, Sasso CF, Amodio M, Magliano P, Salvatore T, Corigliano G, Agrusta M, De Simone G, Gaeta I, Oliviero B, Torella R.

Diabetes Obes Metab. 2000 Dec;2(6):355-62.

PMID:
11225965
4.

Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.

Harley CR, Gandhi SK, Heien H, McDonough K, Nelson SP.

Expert Opin Pharmacother. 2008 Apr;9(5):669-76. doi: 10.1517/14656566.9.5.669.

PMID:
18345946
5.

Antiatherothrombotic properties of statins: implications for cardiovascular event reduction.

Rosenson RS, Tangney CC.

JAMA. 1998 May 27;279(20):1643-50. Review.

PMID:
9613915
6.

Editorial: reducing cardiovascular risk: is low-density lipoprotein-cholesterol (LDL-C) lowering enough?

Kostapanos MS, Katsiki N, Elisaf MS, Mikhailidis DP.

Curr Vasc Pharmacol. 2012 Mar;10(2):173-7. No abstract available.

PMID:
22250844
7.

Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.

Plans-Rubió P.

Am J Cardiovasc Drugs. 2006;6(3):177-88.

PMID:
16780391
8.
9.

Total lipid management and residual risk: beyond statin therapy.

Evans M.

Br J Hosp Med (Lond). 2011 Mar;72(3):132-6. Review.

PMID:
21475092
10.

All at sea: new lipid-lowering drug trials continue to disappoint.

Wierzbicki AS.

Int J Clin Pract. 2013 Jul;67(7):595-8. doi: 10.1111/ijcp.12126. No abstract available.

PMID:
23758438
11.

Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia.

Farnier M, Chen E, Johnson-Levonas AO, McCrary Sisk C, Mitchel YB.

Vasc Health Risk Manag. 2014 May 7;10:279-90. doi: 10.2147/VHRM.S58694. eCollection 2014.

12.

Non-adherence to lipid-lowering therapies: a need for more studies to evaluate reasons for medication non-adherence.

Wong MC, Wang HH, Liu KS.

Int J Clin Pract. 2011 Dec;65(12):1321-2. doi: 10.1111/j.1742-1241.2011.02790.x. No abstract available.

PMID:
22093540
13.

Association between lowering low-density lipoprotein cholesterol with pravastatin and primary prevention of cardiovascular disease in mild to moderate hypercholesterolemic Japanese.

Teramoto T, Nakaya N, Yokoyama S, Ohashi Y, Mizuno K, Nakamura H; MEGA Study Group.

J Atheroscler Thromb. 2010 Aug 31;17(8):879-87. Epub 2010 Jun 11.

14.

Managing dyslipidemia in the high-risk patient.

Stein EA.

Am J Cardiol. 2002 Mar 7;89(5A):50C-57C. Review.

PMID:
11900720
15.

Do patients on statins also need niacin?

Jones KW.

JAAPA. 2013 Jul;26(7):9-10.

PMID:
23923280
16.

Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins.

Andrews TC, Ballantyne CM, Hsia JA, Kramer JH.

Am J Med. 2001 Aug 15;111(3):185-91.

PMID:
11530028
17.

Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.

Cobos A, Jovell AJ, García-Altés A, García-Closas R, Serra-Majem L.

Clin Ther. 1999 Nov;21(11):1924-36.

PMID:
10890264
18.

[Treatment with statins for the reduction of cardiovascular risk].

Chiariello M.

Ital Heart J Suppl. 2001 Mar;2(3):221-3. Review. Italian. No abstract available.

PMID:
11307779
19.

An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).

Smith DG, McBurney CR.

Pharmacoeconomics. 2003;21 Suppl 1:13-23.

PMID:
12648031
20.

[Update: clinical lipidology].

Parhofer KG.

MMW Fortschr Med. 2013 Jul 25;155(13):49-52; quiz 53-4. Review. German. No abstract available.

PMID:
23964509
Items per page

Supplemental Content

Write to the Help Desk